- Home
- CLRB vs CRIS Comparison
CLRB vs CRIS Comparison
Compare CLRB & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLRB | CRIS |
|---|---|---|
| Founded | 2002 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 12.9M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | CLRB | CRIS |
|---|---|---|
| Price | $3.56 | $0.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 130.0K | ★ 1.2M |
| Earning Date | 03-12-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $11,650,000.00 |
| Revenue This Year | N/A | $6.13 |
| Revenue Next Year | N/A | $7.86 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.56 |
| 52 Week Low | $2.45 | $0.77 |
| 52 Week High | $20.60 | $3.57 |
Technical Indicators
Market Signals| Indicator | CLRB | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 53.56 | 43.16 |
| Support Level | $3.33 | $0.87 |
| Resistance Level | $3.98 | $0.98 |
| Average True Range (ATR) | 0.30 | 0.10 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 53.85 | 59.11 |
Price Performance
Historical ComparisonAbout CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.